QT prolongation and proarrhythmia by moxifloxacin: concordance of preclinical models in relation to clinical outcome.
about
Dexrazoxane protects the heart from acute doxorubicin-induced QT prolongation: a key role for I(Ks).Highly automated QT measurement techniques in 7 thorough QT studies implemented under ICH E14 guidelines.Moxifloxacin pharmacokinetic profile and efficacy evaluation in empiric treatment of community-acquired pneumonia.Comparison of the IKr blockers moxifloxacin, dofetilide and E-4031 in five screening models of pro-arrhythmia reveals lack of specificity of isolated cardiomyocytesMoxifloxacin in the treatment of skin and skin structure infections.Inter-individual variability in the pre-clinical drug cardiotoxic safety assessment--analysis of the age-cardiomyocytes electric capacitance dependence.No proarrhythmic properties of the antibiotics Moxifloxacin or Azithromycin in anaesthetized dogs with chronic-AV block.A rabbit Langendorff heart proarrhythmia model: predictive value for clinical identification of Torsades de Pointes.Update on the cardiac safety of moxifloxacin.Wild type and K897T polymorphisms of the hERG gene: modeling the APD in Caucasians.Antimicrobial-associated QT interval prolongation: pointes of interest.Sensitive and reliable proarrhythmia in vivo animal models for predicting drug-induced torsades de pointes in patients with remodelled heartsLiterature-based evaluation of four 'hard endpoint' models for assessing drug-induced torsades de pointes liability.Exposure to antibacterial agents with QT liability in 14 European countries: trends over an 8-year periodQT prolongation in the intensive care unit: commonly used medications and the impact of drug-drug interactions.Antibiotic-induced cardiac arrhythmias.Evidence for the hERG Liability of Antihistamines, Antipsychotics, and Anti-Infective Agents: A Systematic Literature Review From the ARITMO Project.Thorough cardiac QTc interval conductance assessment of a novel oral tranexamic acid treatment for heavy menstrual bleeding.Mechanism of hERG K+ channel blockade by the fluoroquinolone antibiotic moxifloxacin.Recapitulation of Clinical Individual Susceptibility to Drug-Induced QT Prolongation in Healthy Subjects Using iPSC-Derived Cardiomyocytes.Statistical issues of QT prolongation assessment based on linear concentration modeling.A Randomized, Placebo- and Positive-Controlled, Single-Dose, Crossover Thorough QT/QTc Study Assessing the Effect of Daprodustat on Cardiac Repolarization in Healthy Subjects.
P2860
Q33661049-59D3918A-6944-4D53-860F-4345AFD03BF2Q34788845-5673878B-E16F-492B-899F-62EA52E7A43BQ35168927-30F36DFF-304A-4698-85F0-C9426308A66CQ35708176-0C213A76-CFBD-4404-8328-6A86956A6BEAQ35919259-B9E27589-F4E0-4DEA-8CFF-84295F2FA230Q35951965-05ED749B-919B-4A85-A2BE-0A7AA5384061Q36054313-320EFA86-3D25-4DC0-8AD7-59D009082BCAQ36054477-CDF7866E-22AD-406C-8A5E-FF564DB46B32Q36345861-22AB767A-0573-4A75-9579-346F9A642EB6Q36469348-952625E2-0B32-4462-8B30-A31A02007EA7Q36655034-9EF3D8A0-BC7F-489A-8AAD-F1DB9F3A4942Q36801816-8E8C77EB-B0E0-407D-BB7B-BE700C2D8591Q36801832-E6A6C747-E615-4CD8-B658-2AC955A3A2A5Q37156289-F39600A2-A795-44C8-BCCE-6E2196077A15Q37727223-4CBA28A7-E5BA-4214-A209-3AC7D188521CQ38178757-F873B188-9965-4CF7-98F6-1A8CC7B678F4Q39055260-DCCDF7DF-B638-47DE-B01B-9569C36EC222Q39945244-224F4820-660A-458E-8383-3D4261239DE3Q40317287-C3AFB6CC-88D7-4345-92D0-C11559FAB408Q41869132-C86A795C-A9C3-4942-B33B-E608A1F8E151Q46381991-F8154E56-2539-4C1C-B209-C5872AD170F0Q47790423-EA3024DC-14E2-4900-87EE-5B5BEFF44025
P2860
QT prolongation and proarrhythmia by moxifloxacin: concordance of preclinical models in relation to clinical outcome.
description
2005 nî lūn-bûn
@nan
2005 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
QT prolongation and proarrhyth ...... relation to clinical outcome.
@ast
QT prolongation and proarrhyth ...... relation to clinical outcome.
@en
type
label
QT prolongation and proarrhyth ...... relation to clinical outcome.
@ast
QT prolongation and proarrhyth ...... relation to clinical outcome.
@en
prefLabel
QT prolongation and proarrhyth ...... relation to clinical outcome.
@ast
QT prolongation and proarrhyth ...... relation to clinical outcome.
@en
P2093
P2860
P356
P1476
QT prolongation and proarrhyth ...... relation to clinical outcome.
@en
P2093
Corinn M Dahm
Edmund Kadyszewski
Jenifer A Bradley
Jessica D Cass
Michael J Engwall
Zhuoqian Sun
P2860
P304
P356
10.1038/SJ.BJP.0706389
P407
P577
2005-11-01T00:00:00Z